Uber Technologies Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Uber Technologies Inc trades at $71.64 (market cap $146.91B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Uber Technologies Inc is the larger of the two by market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| UBER | VRTX | |
|---|---|---|
Market Cap | $146.91B | $121.95B |
Sector | Industrials | Health |
52-Week High | $100.10 | $529.59 |
52-Week Low | $68.61 | $366.54 |
Enterprise Value | $153.24B | $116.69B |
Signals from Pluang's Aura AI — not financial advice
Uber's stock trades at $72.46, down 2.13% on the day, reflecting near-term pressure amid a bearish technical signal. Fundamentally, the company shows strong revenue growth, with 2025 revenue reaching $52.02 billion and net income of $10.05 billion, though profitability margins have moderated from 2024 peaks. Recent news highlights strategic shifts toward autonomous vehicles, including robotaxi pilots in Europe and cost-cutting measures like HR layoffs and AI spending caps to improve efficiency.
The outlook remains positive with an 81.67% analyst buy rating and a $107.64 consensus price target, suggesting significant upside. Key risks include execution challenges in autonomous vehicle integration, competitive pressures in key markets like India, and potential margin compression. Investors should weigh strong cash flow generation and market leadership against evolving regulatory and technological landscapes.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →